Top

World Journal of Urology

Published in:

Open Access 01-12-2024 | Overactive Bladder | Original Article

The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder

Authors: Magdalena Hagovska, Jan Svihra Sr., Ladislav Macko, Jan Breza Jr., Jan Svihra Jr., Jan Luptak, Lubomir Lachvac

Published in: World Journal of Urology | Issue 1/2024

Abstract

Background

Men with overactive bladder (OAB) and benign prostatic hyperplasia (BPH), will have deterioration in the quality of life.

Objective

The aim of this study was to evaluate the effect of combining pelvic floor muscle training with the urgency suppression technique (PFMT-st) and silodosin in comparison with silodosin in men with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) after 12 weeks of treatment.

Patients and methods

A total of 158 patients were randomized into two groups. The control group received oral silodosin at a daily dose of 8 mg. The experimental group was administered PFMT-st and silodosin. The evaluation methods included the number of voids and intensity of urgencies over 24 h using a micturition diary, the International Prostate Symptom Score (IPSS), the Overactive Bladder Questionnaire (OAB-q), and the patient global impression of improvement (PGI-I).

Results

142 of 172 (86.6%) men were assessed (70 in the control group, 72 in the experimental group). The significant changes were in favor of the experimental group (p < 0.001) in the number of voids per 24 h (− 1.95 ± 1.94 vs. − 0.90 ± 1.44), the OAB-q symptom score (− 14.25 ± 10.05 vs. − 9.28 ± 10.60), the intensity of urgencies (− 0.97 ± 0.53 vs. 0.24 ± 0.57), the IPSS (− 4.59 ± 3.00 vs. − 2.30 ± 3.63), and in the PGI-I (2.24 ± 0.79 vs. 3.60 ± 0.92).

Conclusions

The addition of PFMT-st to silodosin treatment significantly improved OAB in men with BPH. This is the first study to confirm that PFMT-st should be the first-choice treatment for OAB in BPH.

Haylen BT, de Ridder D, Freeman RM et al (2010) An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5–26CrossRefPubMed

D’Ancona C, Haylen B, Oelke M et al (2019) The international continence society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn 38(2):433–477CrossRefPubMed

Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1314CrossRefPubMed

Gravas S, Cornu JN, Gacci M et.al. European association of urology EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Available online: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/. Accessed 28 Oct 2021

Kupelian V, Wei JT, O’Leary MP et al (2006) Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston area community health (BACH) survey. Arch Intern Med 166(21):2381–2387CrossRefPubMed

Chapple C, Herschorn S, Abrams P et al (2009) Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 56:534CrossRefPubMed

Athanasopoulos A, Gyftopoulos K, Giannitsas K et al (2003) Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction:a prospective, randomized, controlled study. J Urol 169:2253CrossRefPubMed

Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296:2319CrossRefPubMed

Matsukawa Y, Takai S, Majima T et al (2019) Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies. Neurourol Urodyn 38:941–949CrossRefPubMed

10.

Matsukawa Y, Funahashi Y, Takai S et al (2017) Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER study). J Urol 197(2):452–458CrossRefPubMed

11.

Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group (2006) Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98:1019–1024CrossRefPubMed

12.

Marks LS, Gittelman MC, Hill LA et al (2009) Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 181:2634–2640CrossRefPubMed

13.

Bo K, Frawley HC, Haylen BT et al (2017) An international urogynecological association (IUGA)/International continence society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. Neurourol Urodyn 36:221–244CrossRefPubMed

14.

Toprak N, Sen S, Varhan B (2022) The role of diaphragmatic breathing exercise on urinary incontinence treatment: a pilot study. J Bodyw Mov Ther 29:146–153CrossRefPubMed

15.

Jerez-Roig J, Souza DL, Espelt A et al (2013) Pelvic floor electrostimulation in women with urinary incontinence and/or overactive bladder syndrome: a systematic review. Actas Urol Esp 37(7):429–444CrossRefPubMed

16.

Silva V, Grande AJ, Peccin MS (2019) Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev 6(4(4)):012044

17.

Notte SM, Marshall TS, Lee M et al (2012) Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder. BMC Urol 12:26CrossRefPubMedPubMedCentral

18.

Cockett ATK, Aso Y, Chatelain C et al (1991) Recommendations of the international concensus committee concerning prostate symptom score (I-PSS) and quality of life assesment. Proceedings of the international consultation on BPH. International Scientific Committee, Paris, France, pp 280–281

19.

Cockett ATK, Khoury S, Aso Y et al. 1993 Recommendations of the International Consensus Committee. In: Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, France, pp. 553–564.

20.

Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the overactive bladder questionnaire (OAB-q). Qual Life Res 14:849–855CrossRefPubMed

21.

Coyne K, Revicki D, Hunt T et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574CrossRefPubMed

22.

Cardozo L, Staskin DR, Currie BM et al (2014) Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder. Int Urogynecol J 25:1655–1663CrossRefPubMedPubMedCentral

23.

Blaivas JG, Panagopoulos G, Weiss JP et al (2007) Validation of the overactive bladder symptom score. J Urol 178:543–547CrossRefPubMed

24.

Yalcin I, Bump RC (2003) Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 189:98–101CrossRefPubMed

25.

Jung JH, Kim J, MacDonald R et al (2017) Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 11(11):012615

Title: The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder
Authors: Magdalena Hagovska
Jan Svihra Sr.
Ladislav Macko
Jan Breza Jr.
Jan Svihra Jr.
Jan Luptak
Lubomir Lachvac
Publication date: 01-12-2024
Publisher: Springer Berlin Heidelberg
Keywords: Overactive Bladder
Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Published in: World Journal of Urology / Issue 1/2024
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-024-04974-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder

Abstract

Background

Objective

Patients and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Do we need MRI in all biopsy naïve patients? A multicenter cohort analysis

Cancer-specific mortality in non-metastatic T1a renal cell carcinoma treated with radiotherapy versus partial nephrectomy

Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer

Pulse modulation in En-Bloc HoLEP: does it really matter? A propensity score matched analysis

The relationship between the force applied and perceived by the surgeon during ureteral access sheath placement: ex-vivo experimental model

Semirigid ureteroscopy and tamsulosin therapy as dilatation methods before flexible ureteroscopy: evaluation and benefits